Table 2.
Baseline demographic and clinical characteristics of tofacitinib-treated patients, overall and by prior biologic history
| Demographics | Overall | Biologic-naïve | 1 prior biologic | ≥ 2 prior biologics |
|---|---|---|---|---|
| N = 225 | N = 43 | N = 92 | N = 90 | |
| Duration of variable-length baseline period (years), mean (SD) | 3.4 (1.8) | 3.4 (1.9) | 3.0 (1.8) | 3.9 (1.8) |
| Age at index date (years), mean (SD) | 45.6 (16.5) | 46.5 (17.1) | 45.5 (15.4) | 45.2 (17.4) |
| Gender, n (%) | ||||
| Female | 113 (50.2) | 22 (51.2) | 49 (53.3) | 42 (46.7) |
| Male | 112 (49.8) | 21 (48.8) | 43 (46.7) | 48 (53.3) |
| 12-month baseline Charlson comorbidity score, mean (SD) | 0.7 (1.3) | 0.5 (1.0) | 0.7 (1.5) | 0.7 (1.2) |
| Prior biologic use, n (%) | ||||
| Adalimumab | 101 (44.9) | 0 (0.0) | 44 (47.8) | 57 (63.3) |
| Infliximab | 87 (38.7) | 0 (0.0) | 28 (30.4) | 59 (65.6) |
| Golimumab | 27 (12.0) | 0 (0.0) | 4 (4.4) | 23 (25.6) |
| Vedolizumab | 90 (40.0) | 0 (0.0) | 16 (17.4) | 74 (82.2) |
| Number of unique biologics, n (%) | ||||
| 0 | 43 (19.1) | 43 (100.0) | NA | NA |
| 1 | 92 (40.9) | NA | 92 (100.0) | NA |
| 2 | 64 (28.4) | NA | NA | 64 (71.1) |
| Vedolizumab + TNFi | 49 (21.8) | NA | NA | 49 (54.4) |
| TNFi + TNFi | 15 (6.7) | NA | NA | 15 (16.7) |
| ≥ 3 | 26 (11.6) | NA | NA | 26 (28.9) |
n, number of patients in the specified category; N, number of patients in the treatment group; NA, not applicable; SD, standard deviation; TNFi, tumour necrosis factor inhibitor